Dissemin is shutting down on January 1st, 2025

Published in

American Society for Microbiology, Antimicrobial Agents and Chemotherapy, 8(59), p. 5032-5035, 2015

DOI: 10.1128/aac.00298-15

Links

Tools

Export citation

Search in Google Scholar

In vitro susceptibility of Leishmania infantum to Artemisinin derivatives and selected trioxolanes.

Journal article published in 2015 by Sofia Cortes, Cristiano Ml, Andreia Albuquerque, Lília I. L. Cabral, Cabral Li, Liliana Lopes ORCID, Lenea Campino, Maria L. S. Cristiano ORCID
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Orange circle
Published version: archiving restricted
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

ABSTRACT Leishmaniasis is among the world's most neglected diseases. Currently available drugs for treatment present drawbacks, urging the need for more effective, safer, and cheaper drugs. A small library of artemisinin-derived trioxanes and synthetic trioxolanes was tested against promastigote and intramacrophage amastigote forms of Leishmania infantum . The trioxolanes LC50 and LC95 presented the best activity and safety profiles, showing potential for further studies in the context of leishmanial therapy. Our results indicate that the compounds tested exhibit peroxide-dependent activity.